Immucell Corp (ICCC) Financial Statements
Industry: In Vitro & In Vivo Diagnostic Substances
In fiscal 2025, Immucell reported revenue of $27.6M, up 4.3% from $26.5M the year before. Net income was -$1.0M (a -3.8% net margin), or -$0.12 per diluted share. Gross margin was 41.4% and operating margin was 6.0%. Operating activities generated $2.5M of cash, leaving $1.2M of free cash flow. At fiscal year end, Immucell held $42.5M in total assets against $15.5M in total liabilities, including $3.8M of cash and equivalents.
Open the full interactive Immucell financials → Quarterly statements, key ratios, valuation history and price charts.
Immucell Key Stats
| Share Price | $10.79 |
|---|---|
| Market Cap | $99.2M |
| Revenue YoY Growth | +4.3% |
| 52-Week Range | $4.56 – $11.72 |
| Shares Outstanding | 9.1 million (basic, 2026 Q2) |
Immucell Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $15.3M | $19.2M | $18.6M | $17.5M | $26.5M | $27.6M |
| Cost of Goods Sold | $8.5M | $10.6M | $10.9M | $13.6M | $18.6M | — |
| Gross Profit | $6.9M | $8.7M | $7.6M | $3.9M | $7.9M | $11.4M |
| Operating Income | -$1.4M | $257,385 | -$2.3M | -$5.7M | -$1.6M | $1.6M |
| Pre-Tax Income | -$1.0M | -$69,127 | -$2.5M | -$5.8M | -$2.1M | -$1.0M |
| Income Tax | -$10,136 | $9,165 | $7,672 | $4,627 | $10,056 | $11,570 |
| Net Income | -$1.0M | -$78,292 | -$2.5M | -$5.8M | -$2.2M | -$1.0M |
| Diluted EPS | -$0.14 | -$0.01 | -$0.32 | -$0.75 | -$0.26 | -$0.12 |
Immucell Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $5.5M | $7.6M | $10.4M | $7.2M |
| Net Income | -$139,748 | -$2.8M | $1.9M | $1.8M |
| Diluted EPS | -$0.02 | -$0.32 | $0.21 | $0.20 |
Immucell Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $6.9M | $10.2M | $5.8M | $978,741 | — | $3.8M |
| Current Assets | $12.2M | $16.3M | $14.0M | — | $15.0M | $16.9M |
| Total Assets | $40.3M | $44.5M | $44.9M | $43.8M | $45.1M | $42.5M |
| Current Liabilities | $2.2M | $2.5M | $3.1M | $4.2M | $4.4M | $4.0M |
| Total Long-Term Debt | $9.5M | $812,207 | $10.2M | $12.0M | $10.5M | $9.1M |
| Total Liabilities | $12.1M | $11.9M | $14.5M | $18.8M | $17.6M | $15.5M |
| Shareholders' Equity | $28.3M | $32.6M | $30.4M | $25.0M | $27.5M | $27.1M |
Immucell Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | $1.3M | $954,170 | -$1.5M | -$4.7M | $357,903 | $2.5M |
| Cash From Investing | -$2.6M | -$1.6M | -$4.0M | -$1.9M | -$461,225 | -$1.2M |
| Cash From Financing | $1.9M | $3.9M | $1.1M | $1.8M | $2.9M | -$1.2M |
| Free Cash Flow | -$2.8M | -$1.7M | -$5.5M | -$6.6M | -$107,822 | $1.2M |
Figures from Immucell's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Immucell financials page for every line item.
Immucell Company Profile
| Ticker | ICCC |
|---|---|
| Exchange | Nasdaq |
| Industry | In Vitro & In Vivo Diagnostic Substances |
| Headquarters | Portland, Maine |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0000811641 |
Frequently Asked Questions
What was Immucell's revenue in fiscal 2025?
Immucell (ICCC) reported revenue of $27.6M for fiscal 2025.
What is Immucell's annual revenue history?
Immucell's annual revenue by fiscal year: 2020: $15.3M; 2021: $19.2M; 2022: $18.6M; 2023: $17.5M; 2024: $26.5M; 2025: $27.6M.
What was Immucell's net income in fiscal 2025?
Immucell reported net income of -$1.0M for fiscal 2025.
What was Immucell's earnings per share (EPS) in fiscal 2025?
Immucell's diluted EPS was -$0.12 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Immucell generate in fiscal 2025?
Immucell generated $1.2M of free cash flow in fiscal 2025.
What was Immucell's revenue last quarter?
In its most recent reported quarter (2026 Q2), Immucell reported revenue of $7.2M.
How much debt does Immucell have?
Immucell reported $9.1M of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of Immucell are outstanding?
Immucell reported a weighted average of 9.1 million basic shares outstanding in 2026 Q2.
What is Immucell's market cap?
Based on its latest closing price, Immucell (ICCC) has a market capitalization of about $99.2M.
When does Immucell's fiscal year end?
Immucell's fiscal year end, as registered with the SEC, is December 31.
Where is Immucell headquartered?
Immucell lists its business address in Portland, Maine in its SEC filings.
Immucell Competitors & Similar Companies
See all 15 In Vitro & In Vivo Diagnostic Substances companies →